

LSL PHARMA GROUP INC.

**TO: Autorité des marchés financiers
 Alberta Securities Commission
 British Columbia Securities Commission
 TSX Venture Exchange**

**AND TO: KPMG LLP / KPMG LLP/s.r.l./s.e.n.c.r.l. (“KPMG”)
 600, Maisonneuve Ouest,
 Suite 1500
 Montréal, Québec, H3A 0A3**

**AND TO: Audacie Inc. (“Audacie”)
 7055 Taschereau Blvd.
 Suite 500
 Brossard, Québec, J4Z 1A7**

**RE: NOTICE OF CHANGE OF AUDITORS (the “Notice”)
 LSL PHARMA GROUP INC. (the “Corporation”)
 Issuer No. 000030902**

NOTICE IS HEREBY GIVEN by the Corporation pursuant to Part 4.11 of National Instrument 51-102 (“NI51-102”), as follows:

In accordance with Part 4.11 of NI51-102 we confirm that:

- a) KPMG has resigned as auditor of the Corporation effective September 25, 2024 at the request of the Corporation to facilitate the appointment of Audacie as successor auditor of the Corporation;
- b) The resignation of KPMG (the “**Predecessor Auditor**”) and the appointment of Audacie effective September 25, 2024 as auditor of the Corporation (the “**Successor Auditor**”) were considered and recommended by the Audit Committee and approved by the Board of Directors of the Corporation;
- c) There is no auditor’s report of the Predecessor Auditor on the financial statements of the Corporation for the two years ended December 31, 2023 and 2022 or any subsequent period until its resignation date which expressed modified opinions as to departures from generally accepted accounting principles or limitation in the scope of the audit; and
- d) There are no reportable events.

Dated this 25th day of September, 2024

LSL PHARMA GROUP INC.

(Signed) Luc Mainville

Per: Luc Mainville,
Executive Vice-President and Chief Financial Officer